Skip to content
HowShorted

Bionano Genomics, Inc. short interest in 2021

In 2021, Bionano Genomics, Inc.'s disclosed short interest ran from 16.63% of shares outstanding on 15 Jan 2021 to 14.01% on 31 Dec 2021, a change of -2.62 percentage points. The year's high was 18.70% on 30 Jun 2021 and its low 8.53% on 15 Mar 2021, averaging 14.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.62 days on 15 Sep 2021. Full history: Bionano Genomics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Bionano Genomics, Inc. in 2021

2021 in figures

Start of year
16.63% (15 Jan 2021)
End of year
14.01% (31 Dec 2021)
Change
-2.62 pp
High
18.70% (30 Jun 2021)
Low
8.53% (15 Mar 2021)
Average
14.11%
Highest days to cover
6.62 (15 Sep 2021)
SEC filings marked
10

Every report in 2021

Bionano Genomics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202116.63%1.00results (8-K)
29 Jan 202117.43%1.00results (8-K)
12 Feb 202112.44%1.00
26 Feb 202114.31%1.00
15 Mar 20218.53%1.00
31 Mar 202110.26%1.5910-K filed, results (8-K)
15 Apr 202110.41%2.33
30 Apr 202111.32%1.02
14 May 202113.12%2.0010-Q filed, results (8-K)
28 May 202113.82%2.10
15 Jun 202113.73%1.40
30 Jun 202118.70%2.80
15 Jul 202116.12%3.70
30 Jul 202115.00%4.89
13 Aug 202116.26%5.1510-Q filed, results (8-K)
31 Aug 202116.26%5.93
15 Sep 202115.94%6.62
30 Sep 202114.45%4.62
15 Oct 202115.06%6.05
29 Oct 202113.62%5.90
15 Nov 202112.97%3.1910-Q filed, results (8-K)
30 Nov 202113.89%4.25
15 Dec 202114.34%4.90
31 Dec 202114.01%5.02

See also: Bionano Genomics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.